

PHARMACY POLICY STATEMENT

Marketplace

DRUG NAME	Enjymo (sutimlimab)
BILLING CODE	J3590
BENEFIT TYPE	Medical



CareSource considers Enjaymo (sutimlimab) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
03/21/2022	New policy for Enjaymo created.

References:

1. Enjaymo [package insert]. Waltham, MA; Bioverativ USA Inc. February 2022.
2. Tvedt THA, et al. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. *Am J Hematol.* 2022 Feb 1;97(2):E51-E54.
3. Röth A, et al. Sutimlimab in Cold Agglutinin Disease. *N Engl J Med.* 2021 Apr 8;384(14):1323-1334.
4. Gabbard AP, Booth GS. Cold Agglutinin Disease. *Clin Hematol Int.* 2020;2(3):95-100.

Effective date: 10/01/2022
Revised date: 03/21/2022